Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study ...Middle East

STOCKHOLM, Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has dosed...

Hence then, the article about medivir s licensee tango therapeutics has dosed the first patient with tng348 a novel usp1 inhibitor in a phase 1 2 clinical study was published today ( Thursday 04/01/2024 - 10:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study )

Also on site :

• Thousands rally in Serbia as students continue fight against corruption
• 'SNL' Parodies 'Heated Rivalry' With Harry Potter Characters — And a Genius Cameo
• Iran’s Supreme Leader Ali Khamenei blames Trump for deadly protests